Clinical trial

Skin irritation
#Clinical trial #Destiny Pharma #Ringworm

A potential new agent for the treatment of fungal skin infections 

Destiny Pharma has announced new data on one of its compounds, XF-70, which has demonstrated potency in an in vivo model of ringworm, a common fungal skin infection, which affects up to one in four people worldwide.   Ringworm is caused by a class of fungi called… Read More

#News

Gene therapy
#Clinical trial #Gene therapy #Genetics / genomics #Hearing Loss #Paediatrics #Regeneron Pharmaceuticals

Gene therapy restores hearing in both ears

Five children who were born with congenital hearing loss can hear in both ears after taking part in a gene therapy trial at Fudan University in Shanghai, China. Within weeks of receiving the therapy, the children could locate the sources of sounds, and recognised speech in… Read More

#News

Vaccine
#Clinical trial #Immunology / Virology & Vaccines #Interview #University of Oxford #Vaccines

Vaccines and various response rates

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the… Read More

#Exclusive Content

Human brain
#Clinical trial #Neuroscience #Newron Pharmaceuticals #Schizophrenia

Study in schizophrenia patients shows positive top-line results 

Newron Pharmaceuticals has announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment.   The… Read More

#News

Child receiving treatment for malaria
#Africa #Clinical trial #Malaria #Monoclonal antibodies #Therapeutic Antibodies

Experimental malaria monoclonal antibody prevents infection

A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. L9LS binds to and neutralises ‘sporozoites’, the form of the malaria parasite transmitted by mosquitoes that… Read More

#News #Trending News

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

New DDW Highlights podcast: 29 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The leading news story this week has been the launch of a new clinical… Read More

#News

#Cancer research #Cancer vaccine #CAR-T #Clinical trial #Oncology #Personalised medicine

This week in drug discovery (22-26 April) 

News round-up for 22-26 April by DDW Digital Content Editor Diana Spencer. The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

New DDW Highlights podcast: 22 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headline news this week all concerns clinical trials for new drugs that could… Read More

#News

Cancer research
#Acute inflammatory conditions #Clinical trial #KMO inhibitor #Kynos Therapeutics #Phase I trial #University of Edinburgh

Positive Phase I results for KMO inhibitor in inflammatory disorders

Kynos Therapeutics has announced positive top line results from the first in human Phase I trial of its lead drug candidate, KMO inhibitor KNS366, for acute and chronic inflammatory disorders. KMO is an enzyme that acts at a key point in the kynurenine pathway of… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Clinical trial #Clinical trials #Cystic fibrosis #Parkinson's #TB

This week in drug discovery (15-19 April) 

News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer. The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. Read More

#News

#Clinical trial #Obesity #Phase II trial #Trial data #Viking Therapeutics

Positive results for dual GLP-1/GIP receptor agonist in obesity

Viking Therapeutics has reported positive top-line results from the Phase II VENTURE trial of VK2735 in patients with obesity. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The study demonstrated statistically significant reductions in body… Read More

#News

Scientist in modern laboratory
#Cancer research #Clinical trial #CureLab Oncology #Oncology #Phase I trial

Study undermines mechanism-based discovery, says CureLab

CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. The study shows that disease progression was significantly delayed in a group of stage III and IV platinum-resistant ovarian cancer (PROC) patients who received gemcitabine in combination with… Read More

#Cancer Research #Editor's Choice #News

Hands with frostbite
#Clinical trial #Eicos Sciences #FDA #Regulatory

First drug for severe frostbite helps prevent amputation

The US Food and Drug Administration (FDA) has approved Eicos Sciences’ Aurlumyn (iloprost) injection, the first FDA-approved medication to treat severe frostbite. “This approval provides patients with the first-ever treatment option for severe frostbite,” said Norman Stockbridge, Director of the Division of Cardiology and Nephrology in the FDA’s Center for… Read More

#News #Regulatory

Monoclonal antibodies
#Clinical trial #Dermatology #Monoclonal antibodies #Phase III trial #UCB

Monoclonal antibody improves hidradenitis suppurativa by 55%

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February). Emmanuel… Read More

#News

Clinical trial
#Autoimmune disease #Clinical trial #Phase II trial #Vera Therapeutics

Drug shows disease-modifying effect in IgA nephropathy

Vera Therapeutics has announced positive 72-week data from the open label extension (OLE) period of its Phase IIb ORIGIN clinical trial of atacicept in participants with IgA nephropathy (IgAN). In aggregate, the 72-week data with atacicept are consistent with a profile of true disease modification in… Read More

#News

Doctor looks at x-ray of the lungs
#Clinical trial #Drug delivery #Immunology / Virology & Vaccines #TB #TB vaccine #University of Oxford

Clinical trial will test novel inhaled TB vaccine

A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. Read More

#News